Investor Relations

Company Overview

Baudax Bio is a pharmaceutical company focused on developing and commercializing innovative products for patients in rare disease settings. We believe we can create value for healthcare providers, patients, and shareholders through our portfolio of products, which also includes a robust pipeline of product candidates. In addition, we continue to evaluate acquisition and licensing opportunities that align with our core acute care focus.

Our product candidate pipeline includes early-stage product candidates, including a recently acquired TCR Treg platform, two novel neuromuscular blocking agents (NMBAs), and a related proprietary chemical reversal agent.

Investor Contact Information


Baudax Bio, Inc.
490 Lapp Road
Malvern, PA 19355
T: 484-395-2440
F: 484-395-2471

Investor Relations

LifeSci Advisors
Mike Moyer